IPOs and Secondaries
IPOs and Secondaries Articles
Azure Power Global has amended its filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
U.S. Foods has amended it filing with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Published:
Last Updated:
United Guaranty has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Spotify raised another $1 billion in funding in a deal that is expected to close this week, but the catch is that it has virtually guaranteed an initial public offering as a condition of the capital...
Published:
Last Updated:
ContraVir Pharmaceuticals stock shot up following positive results from a hepatitis B study earlier this week, but now it is back down after the pricing of a secondary offering was announced.
Published:
Last Updated:
BioPharmX saw its shares take a sharp downward turn following the announcement of a secondary offering.
Published:
Last Updated:
Aeglea BioTherapeutics expects to price more than 3 million shares in a range of $16 to $18 per share for an initial public offering valued up to more than $72 million.
Published:
Last Updated:
Tactile Systems Technology has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
The month of March yielded 5 initial public offerings (IPOs), not a magnificent total, but more than half of all IPOs in the first quarter. After all, there have been just 8 new public offerings in...
Published:
Last Updated:
Celator Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Published:
Last Updated:
Vitae Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering valued at up to $40 million.
Published:
SecureWorks has amended its filig with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Jefferies has raised the target on Apollo Global Management to $20 a share while maintaining a Buy rating on the stock.
Published:
Last Updated:
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Moleculin Biotech plans to list up to 2 million shares at an estimated $5.50 apiece in an IPO valued at up to $11 million.
Published:
Last Updated: